2026 · 2nd Quarter (Apr 1 - June 30)

DAIICHI SANKYO, INC.

Filed by TIBER CREEK GROUP.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 18, 2026
Income: $50,000.00
Expenses: Not reported
Registrant: TIBER CREEK GROUP
Client: DAIICHI SANKYO, INC.
Filing UUID: 65cc0438-1a61-4cc3-a43b-966a93dd8581
Termination date: Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Literal federal measure citations: H.R. 4299

MMM · Medicare/Medicaid

Issues related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the implementation of the American Relief Act of 2025 (PL 118-158); Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Literal federal measure citations: H.R. 4299

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.